Status:
UNKNOWN
Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia
Lead Sponsor:
Hadassah Medical Organization
Collaborating Sponsors:
Hebrew University of Jerusalem
Conditions:
Fibromyalgia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective of the study is to evaluate the effectiveness of oral tetrahydrocannabinol in patients suffering from Fibromyalgia
Eligibility Criteria
Inclusion
- \- Adult (\>18y.o) Patient with Fibromyalgia, diagnosed by ACR criteria
Exclusion
- \- Children \< 18 years old
- Patients with following psychiatric disorders:
- Psychosis or history of acute psychosis
- Schizophrenia
- Bipolar disorder Patients smoking marijuana, using hashish or any other form of cannabis. Patients with history of drug abuse or illicit drug use Patients receiving chronic treatment with strong opioids (Morphine, Oxycodone, Fentanyl, Methadone, Hydromorphone, Buprenorphine, Pethidine). Weak opioids as Tramadol or Propoxyphene will be allowed.
- Pregnant patients
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01149018
Start Date
June 1 2010
End Date
October 1 2012
Last Update
June 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pain Relief Unit, Hadassah Medical Organisation
Jerusalem, Israel, 91120